赵, 丰 – page 9 – eisai china lnc.-nba直播小9直播

 赵, 丰 – page 9 – eisai china lnc.-nba直播小9直播

entries by

shanghai tennry and eisai china inc. reached a strategic cooperation in the chinese market

shanghai tenry pharmaceutical company limited (hereinafter referred to as “shanghai tenry”) and eisai china inc. signed a marketing service agreement. shanghai tengry is responsible for the market promotion of glufast® (mitiglinide calcium tablets), a diabetes treatment drug, in china, and the two parties will work hand in hand to serve the vast population of diabetic patients in china.

applications based on progression-free survival, overall survival, and objective response rate data from respective pivotal phase 3 trials

eisai and bristol myers squibb enter into global strategic collaboration for eisai’s morab-202 antibody drug conjugate

tokyo and new york, june 18, 2021 — eisai co., ltd. and bristol-myers squibb company (nyse: bmy) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of morab-202, an antibody drug conjugate (adc). morab-202 is eisai’s first adc and combines eisai’s in house developed anti-folate receptor alpha (frα) antibody, and eisai’s anticancer agent eribulin, using an enzyme cleavable linker. it is a potential best-in-class frα adc with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. eisai is currently investigating morab-202 in frα-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a phase 1 clinical study in japan and a phase 1/2 clinical study in the united states. the companies are planning to move into the registrational stage of development for this asset as early as next year.

tokyo and kenilworth, n.j., june 7, 2021 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada) today announced new investigational data from the pivotal phase 3 clear(study 307)/keynote-581 trial, which evaluated the combinations of lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by eisai, plus keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a., and lenvima plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (rcc). results from a new analysis evaluating health-related quality of life (hrqol) based on patient-reported outcomes are being presented during an oral abstract session at the 2021 american society of clinical oncology (asco) annual meeting (abstract #4502). data from clear/keytnote-581 were originally presented at the 2021 genitourinary cancers symposium (asco gu) and published in the new england journal of medicine, and data from this trial are currently under review with the u.s. food and drug administration (fda).

applications based on progression-free survival, overall survival, and objective response rate data from respective pivotal phase 3 trials

网站地图